Fertility
“We gravitate towards things that are instantly gratifying. IVF is one of them”
As the global IVF market is estimated to reach US$36.2b by 2026, embryologist Cynthia Hudson tells FemTech World why IVF has become the logical response when struggling to conceive.
It is estimated that infertility affects one in seven heterosexual couples in the UK.
Since the original NICE guideline on fertility published in 2004 there has been an increase in the prevalence of fertility problems and a greater proportion of people seeking treatment.
A study from 2021 published in Sociology of Health & Illness found that in the UK, IVF is presented as an entirely predictable, and linear course of action when dealing with infertility.
The increasing age at which women start families, declining male fertility along with greater social acceptance of fertility treatment has meant the market has been enjoying steady growth in recent years and so has IVF.
“If a couple runs into a perceived level of infertility, the quickest way to get pregnant statistically, is to do IVF,” says Cynthia Hudson, embryologist and VP of clinical strategy at TMRW Life Sciences.
“The reason why the odds are stacked so heavily in our favour is because we can effectively condense time. We can stimulate the ovaries to produce multiple eggs at once, as opposed to the typical menstrual cycle output of one egg per month.
“But there is a certain level of impatience in our world, and we tend to gravitate towards things that can get us to our stated goals faster. In the rush, we may not take the time to understand all of the reasons behind the infertility.”
There is a lack of awareness around what might require IVF and what might not, says Hudson. Age, lifestyle choices and timing are often overlooked, although they play an important role in achieving parenthood.
“IVF may be required as part of your fertility journey, but it’s also important to treat what the symptom is in the first place, if it is possible to do so,” Hudson explains.
“Age is the most significant predictor of success. So, if you are 25 and you’re not achieving quick success, it’s unlikely that the eggs are the cause of the problem. It could be a timing issue or an issue on the male side.
“If you’re in your 40s, however, it is likely that age is why you can’t become pregnant – your chance of success is reduced. I think it’s important to accelerate the decision-making process at this point.
“You don’t need a fertility specialist to tell you that you’re 42. But sometimes we just get impatient, and we don’t take the time to investigate the cause. We will go right to solution, rather than try to see if we can figure it out.”
During IVF, an egg is removed from the woman’s ovaries and fertilised with sperm in a laboratory. The fertilised egg or the embryo is then returned to the woman’s womb to grow and develop.
As embryos vary in quality, research has predominantly focused on advancing the methods of selecting embryos. However, scientists are now looking at ways to improve the gamete and embryo quality to begin with.
“We’ve spent a lot of time investigating how to screen the embryos and choose the best of the cohort, but what we haven’t really done is improve the egg and sperm cohorts to begin with,” says Hudson, adding that working on the development and growth of the gametes is an exciting area.
“At this point, all we can do is take the material that we have, and then put them together. But what we want to do is try and make that cohort develop better, so that we could improve success rates both in vitro (IVF) and in vivo (in the human body), and help couples conceive without IVF in the first place.”
Cellular reprogramming – the act of reverting mature, specialised cells into induced pluripotent stem cells – is another interesting area of research, says Hudson.
“This means you would get a cheek swab, you would submit that to a lab and the researchers would then deprogram those cells back to where they were at their earliest point. Then they would get those together with an egg or a sperm and eventually, grow an embryo out of that without having to go through the entire egg retrieval cycle.
“Although this is not something that we are likely to see in the next five years, it remains an area that will be further explored.”
Currently, many couples still face barriers to getting fertility treatment. According to the World Health Organisation (WHO), between 48 million couples and 186 million individuals struggle with infertility globally, but only three per cent have access to IVF and similar treatments.
Disparities – largely determined by complex social, cultural, racial, and economic factors – require further studies and cultural enrichment.
For embryologists like Hudson, improving access to fertility treatment remains a priority.
“The vast majority of humans do not have access to fertility treatment and that’s a tragedy. I think we owe it to ourselves and our fellow humans to change that.
“I would like to get to a place where we can say what definitively does or does not work in the lab to improve pregnancy rates. We need to stop charging people for treatments that haven’t been proven clinically beneficial”, the expert adds.
“There are a lot of manual steps in the IVF process right now and we’re at a point where we need to standardise these in order to help us figure out how to improve. I’ve focused a lot of my time recently trying to raise the bar and automate some of those processes.
“We need to make sure that we don’t leave things to chance. We don’t have the infrastructure yet, but we’re getting there.”
For more info about TMRW Life Sciences, visit tmrw.org.
Housing, work and fertility pressures are stopping many Britons growing the families they want, new research suggests.
A UK fertility report found that 79 per cent of people surveyed who had tried to conceive in the past five years would like more children than they currently have.
Among parents with one child, that figure rises to 88 per cent.
The report surveyed more than 1,000 people across the UK who had tried for a baby in the past five years.
While birth rates continue to fall, the findings suggest it is not because people no longer want children. Instead, many respondents said external pressures are making it harder to grow their families.
The findings, from wellness brand Wild Nutrition’s Fertility Disconnect report, highlight how financial pressures, fertility struggles and gaps in reproductive health knowledge are shaping modern family life in the UK.
Gail Madalena, fertility nutritional therapist at Wild Nutrition, said: “People often assume fertility begins the moment they decide to try [for a baby].
“In reality, egg and sperm health are shaped months and years earlier.
“By the time someone starts thinking about fertility, their body has already been responding to its environment for a long time.”
Among the biggest barriers, 26 per cent said career progression affected their family plans, 25 per cent cited housing affordability and lack of space, and 52 per cent said they required medical intervention during their fertility journey.
The report also found that almost a quarter of respondents had spent more than two years trying to conceive.
Trying for a baby can take a significant toll on mental health and relationships, especially for those navigating fertility treatment.
According to the research, 38 per cent of respondents said trying to conceive had negatively affected their mental health. That figure rose to 99 per cent among people undergoing fertility treatment.
Julianne Boutaleb is a perinatal psychologist.
She said: “Navigating a fertility journey is about so much more than medical appointments and procedures.
“It’s an emotional marathon that can take a huge toll on your mental wellbeing.
“Sadly, the stats show that 15 per cent of couples going through fertility treatment say their relationship has been irrevocably impaired.”
The report also highlighted the realities of secondary infertility, which affects around one in 20 people, challenging the assumption that having one child means conceiving again will be straightforward.
Researchers found many people felt under-informed about fertility, particularly younger adults.
Ten per cent of Gen Z respondents said they “know nothing” about fertility, while only one in five respondents said they know “a lot” about egg health.
The report also found that 60 per cent of women were unaware of fertility testing options, and one in five Gen Z respondents said they felt uncomfortable discussing fertility, even with their partner.
Around 40 per cent of those surveyed supported fertility education being included in schools, covering topics such as egg health, sperm health and hormonal health.
The report also explored how lifestyle and long-term health may influence fertility outcomes.
Many respondents said they only made changes once they started trying to conceive.
Some 44 per cent improved their diet when trying for a baby, while 32 per cent reduced alcohol intake at that stage.
The report also referenced emerging research that suggests ultra-processed foods and microplastics could have an impact on reproductive health.
While fertility conversations often focus on women, the findings showed male fertility issues are also affecting many families.
Seventeen per cent of respondents cited sperm health issues as a barrier to conception, while male factors contribute to around half of all fertility challenges.
Only one in four men said they would share fertility struggles with friends.
“Many causes of male infertility are entirely treatable yet so often the last resort is the first response,” said Ian Stones, co-founder at Test Him Ltd.
The findings come as UK birth rates remain below replacement level.
The report noted that the UK fertility rate is now 1.41, meaning that on average women give birth to 1.41 children over their lifetimes. The replacement rate, or rate that maintains population numbers, is 2.1.
It also said the average age of mothers has risen to 31, while birth rates are falling across most age groups except among over-40s.
“There is no single fertility story, and it is rarely a simple, linear narrative,” said Dr Zeynep Gurtin, lecturer in women’s health at UCL.
Dr Gurtin added that better fertility education, fairer access to treatment and more open conversations around infertility and pregnancy loss are needed.
Femtech World is thrilled to reveal the shortlist for the Fertility Innovation Award.
The award, sponsored by FinDBest IVF, celebrates a pioneering product, service or initiative that is transforming fertility care and support.
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
This year’s nominees represent a remarkable breadth of approaches to fertility care: from clinic-floor breakthroughs to at-home hormone intelligence to truly borderless access.
Three companies made the cut, with each tackling a real, persistent barrier in reproductive health.
Congratulations to the shortlist and many thanks to everyone who entered.
Fertility Innovation Award Shortlist
HRC Fertility’s Needle-Free IVF is a pioneering advancement designed to transform one of the most challenging aspects of fertility treatment: daily hormone injections.
Developed by board-certified reproductive endocrinologist Dr Rachel Mandelbaum, this innovative approach reimagines how stimulation medications are delivered during IVF and egg freezing, dramatically improving the patient experience while maintaining the same trusted clinical outcomes.
Inspired by feedback from patients who struggled with the injection process, Dr Mandelbaum adapted an innovative drug-delivery system commonly used in other areas of medicine and applied it to reproductive care
Mira is a hormonal health technology company that provides lab-grade hormone testing and AI-driven insights to help women and couples understand their fertility.
The platform has already supported more than 200,000 couples on their fertility journeys worldwide, helping over 60,000+ users achieve pregnancy.
For some users, pregnancy rates have reached up to 89 per cent within six months, demonstrating how accurate hormone data can significantly improve fertility outcomes.
Founded in 2021 by Marija Skujina, a Certified Fertility Nurse Specialist accredited by the European Society of Human Reproduction and Embryology, with nearly 15 years of clinical experience at one of the world’s top IVF clinics, and having navigated her own fertility journey as a patient, Marija built the clinic she had always wished existed.
Plan Your Baby began with a bold, but simple mission – make best quality fertility and pregnancy available anywhere.
Plan Your Baby has created a new generation fertility and pregnancy clinic with patients accessing expert consultations remotely, while blood tests and ultrasound scans are available at over 450 locations across the UK, eliminating the exhausting travel burden that often forces people to take days off work, relocate appointments, or abandon treatment altogether
What happens now
The shortlist will be judged by a representative from category sponsor FindBestIVF, with the winner announced at a virtual event on June 19.
Winners will receive a trophy and be interviewed by a Femtech World journalist.
The first patients have been dosed in a UK miscarriage trial testing a new intravaginal drug delivery platform for threatened miscarriage.
The FREEDOM study is evaluating 400mg progesterone Callavid in patients diagnosed with luteal phase insufficiency, a condition in which progesterone levels may be too low to support early pregnancy, increasing the risk of infertility and recurrent miscarriage.
Callavid uses a patented leak-free, tampon-like design intended to address the limitations of current vaginal treatments, which rely on self-administered pessaries, or vaginal suppositories, that can leak and may move during use.
The device is being developed by London-based Calla Lily Clinical Care, a medical technology company focused on women’s health. The trial is funded by the National Institute for Health and Care Research and run in collaboration with the Trial Management Unit at University Hospitals Coventry and Warwickshire NHS Trust.
According to the company, Callavid is positioned to become the world’s first drug-device combination product to support treatment of threatened miscarriage, as well as luteal phase support as part of assisted reproductive technologies, including in vitro fertilisation, or IVF.
The Government’s Renewed Women’s Health Strategy for England cites estimates ranging from 120,000 to 250,000 cases of miscarriage a year in the UK. Administering 400mg micronised progesterone twice daily is recommended by the National Institute for Health and Care Excellence for women who have suffered a previous miscarriage and experience bleeding during early pregnancy, known clinically as threatened miscarriage.
Current pessary delivery methods can result in uncertain placement and movement during use. These limitations can reduce the efficiency and consistency of drug absorption, potentially compromising delivery of the intended dose, and patients are regularly advised to lie horizontal for extended periods after each administration.
The FREEDOM trial is led by professor Siobhan Quenby MBE, an authority on miscarriage and preterm birth, and an honorary consultant at University Hospitals Coventry and Warwickshire NHS Trust. The study aims to evaluate safety, user acceptability and progesterone absorption, with the goal of providing evidence of improved usability in self-administration.
Quenby commented: “Through my clinical practice, I see the difficulties patients face with existing vaginal progesterone products at an already very stressful time. Callavid offers a promising new solution to ensure delivery of the correct progesterone dosage and give women greater confidence in their treatment. There is genuine excitement among both clinicians and patients at the prospect of Callavid progressing into clinical trials.”
Dr Lara Zibners, co-founder and chair of Calla Lily Clinical Care, added: “As a physician and entrepreneur, I believe we have a responsibility to create more effective, patient-centred solutions in women’s health. Having been through seven rounds of IVF myself, I have experienced how difficult progesterone treatment can be, and I am proud to be advancing an innovation shaped by both medical insight and lived experience.”
Thang Vo-Ta, co-founder and chief executive of Calla Lily Clinical Care, said: “Dosing the first patients in the FREEDOM study marks a critical milestone for Calla Lily Clinical Care. Callavid represents a differentiated delivery modality for a broad range of therapeutics in the pharma pipeline, and will create new opportunities to extend the lifecycle of existing drugs. This trial is a key step in demonstrating Callavid’s massive potential.”
Entrepreneur3 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News2 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Diagnosis4 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Diagnosis3 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Menopause4 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health3 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Entrepreneur4 weeks agoFlora Fertility closes US$5m seed round
News3 weeks agoResistance training has preventative effects in menopause, study finds
Pingback: Exposing IVF errors key to improving standard of care, say embryologists - FemTech World